newsfilter
← Latest News
PR Newswire·

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

-- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 27 of 38 (71%) evaluable patients reached CR/sCR; 20 of 25 patients (80%) dosed > 12